Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Predictors for achieving protein and energy requirements in undernourished hospital patients.

Leistra E, Willeboordse F, van Bokhorst-de van der Schueren MA, Visser M, Weijs PJ, Haans-van den Oord A, Oostenbrink J, Evers AM, Kruizenga HM.

Clin Nutr. 2011 Aug;30(4):484-9. doi: 10.1016/j.clnu.2011.01.008. Epub 2011 Mar 3.

PMID:
21376433
2.

Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research.

Oostenbrink JB, Al MJ, Oppe M, Rutten-van Mölken MP.

Value Health. 2008 Dec;11(7):1070-80. doi: 10.1111/j.1524-4733.2008.00389.x.

3.

Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain.

Rutten-van Mölken MP, Oostenbrink JB, Miravitlles M, Monz BU.

Eur J Health Econ. 2007 Jun;8(2):123-35. Epub 2007 Mar 17.

4.

Economic costs of minor depression: a population-based study.

Cuijpers P, Smit F, Oostenbrink J, de Graaf R, Ten Have M, Beekman A.

Acta Psychiatr Scand. 2007 Mar;115(3):229-36.

PMID:
17302623
5.

Costs of nine common mental disorders: implications for curative and preventive psychiatry.

Smit F, Cuijpers P, Oostenbrink J, Batelaan N, de Graaf R, Beekman A.

J Ment Health Policy Econ. 2006 Dec;9(4):193-200.

PMID:
17200596
6.

Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?

Rutten-van Mölken MP, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU.

Chest. 2006 Oct;130(4):1117-28.

PMID:
17035446
7.

Cost assessment and price setting of inpatient care in The Netherlands. the DBC case-mix system.

Oostenbrink JB, Rutten FF.

Health Care Manag Sci. 2006 Aug;9(3):287-94.

PMID:
17016935
8.

The risk of upcoding in casemix systems: a comparative study.

Steinbusch PJ, Oostenbrink JB, Zuurbier JJ, Schaepkens FJ.

Health Policy. 2007 May;81(2-3):289-99. Epub 2006 Aug 14.

PMID:
16908086
9.

Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.

Oostenbrink JB, Rutten-van Mölken MP, Monz BU, FitzGerald JM.

Value Health. 2005 Jan-Feb;8(1):32-46.

10.

A comparative study of resource use and costs of renal, liver and heart transplantation.

Oostenbrink JB, Kok ET, Verheul RM.

Transpl Int. 2005 Apr;18(4):437-43.

11.

Assessment of exposure to wheat flour and the shape of its relationship with specific sensitization.

Peretz C, de Pater N, de Monchy J, Oostenbrink J, Heederik D.

Scand J Work Environ Health. 2005 Feb;31(1):65-74.

12.

The analysis of incomplete cost data due to dropout.

Oostenbrink JB, Al MJ.

Health Econ. 2005 Aug;14(8):763-76.

PMID:
15729743
13.

Resource use and risk factors in high-cost exacerbations of COPD.

Oostenbrink JB, Rutten-van Mölken MP.

Respir Med. 2004 Sep;98(9):883-91.

14.

Application of a diagnostic decision rule in children with meningeal signs: a cost-minimization study.

Oostenbrink R, Oostenbrink JB, Moons KG, Derksen-Lubsen G, Grobbee DE, Redekop WK, Moll HA.

Int J Technol Assess Health Care. 2003 Fall;19(4):698-704.

PMID:
15095776
15.

One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease.

Oostenbrink JB, Rutten-van Mölken MP, Al MJ, Van Noord JA, Vincken W.

Eur Respir J. 2004 Feb;23(2):241-9.

16.

Methods to analyse cost data of patients who withdraw in a clinical trial setting.

Oostenbrink JB, Al MJ, Rutten-van Mölken MP.

Pharmacoeconomics. 2003;21(15):1103-12.

PMID:
14596629
17.

Unit costs of inpatient hospital days.

Oostenbrink JB, Buijs-Van der Woude T, van Agthoven M, Koopmanschap MA, Rutten FF.

Pharmacoeconomics. 2003;21(4):263-71.

PMID:
12600221
18.

Cost-utility analysis of patient care in children with meningeal signs.

Oostenbrink R, Oostenbrink JB, Moons KG, Derksen-Lubsen G, Essink-Bot ML, Grobbee DE, Redekop WK, Moll HA.

Int J Technol Assess Health Care. 2002 Summer;18(3):485-96.

PMID:
12391942
19.

Standardisation of costs: the Dutch Manual for Costing in economic evaluations.

Oostenbrink JB, Koopmanschap MA, Rutten FF.

Pharmacoeconomics. 2002;20(7):443-54.

PMID:
12093300
20.

Cost-effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery.

Oostenbrink JB, Tangelder MJ, Busschbach JJ, van Hout BA, Buskens E, Algra A, Lawson JA, Eikelboom BC; Dutch Bypass Oral anticoagulants or Aspirin (BOA) Study Group.

J Vasc Surg. 2001 Aug;34(2):254-62.

21.

Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands.

Oostenbrink JB, Rutten-van Mölken MP, Sluyter-Opdenoordt TS.

J Glaucoma. 2001 Jun;10(3):184-91.

PMID:
11442180
22.

Costs of outpatient anticoagulant treatment in patients with cerebral and peripheral arterial occlusive disease.

Gorter JW, Oostenbrink JB, Tangelder MJ; Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group; Dutch Bypass, Oral Anticoagulants or Aspirin Study(BOA).

Thromb Haemost. 2001 Jan;85(1):52-6.

PMID:
11204588
24.

Oral contraceptives in the treatment of Darier-White disease--a case report and review of the literature.

Oostenbrink JH, Cohen EB, Steijlen PM, van de Kerkhof PC.

Clin Exp Dermatol. 1996 Nov;21(6):442-4. Review.

PMID:
9167343

Supplemental Content

Loading ...
Support Center